Investment
Features
FeesSafety
Academy
More
Pluang+

Bitcoin dominance remains elevated above 55% in 2026 due to institutional ETF inflows, limiting altcoin rallies.

Market News
24 Aug 2026
Crypto news
View Source
Neutral
Bitcoin dominance remains elevated above 55% in 2026 due to institutional ETF inflows, limiting altcoin rallies.

Bitcoin dominance (BTC.D), the share of bitcoin's market cap relative to the total crypto market, has stayed in the mid to high 50s in 2026 after peaking above 63% in 2025. This sustained high level is driven by large institutional inflows via spot bitcoin ETFs launched in 2024, which channel capital exclusively into bitcoin, creating a structural floor for BTC.D. Although altcoins have seen brief rallies, ETF inflows keep dominance elevated, dampening broad altcoin seasons. Investors should interpret BTC.D alongside total market cap to understand market regimes and note that the ETF era has altered historical dominance patterns, making altcoin rotations less pronounced and slower than in previous cycles.

More News

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...

Others
Neutral
42 minutes ago
EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...

Company Fundamentals
Neutral
42 minutes ago
Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...

Market News
Bullish
42 minutes ago
Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics announced that Mark Vale, former UPS president and current CEO of Transportation Insight, will join its board and chair the audit committee after its merger with Churchill Capital Corp XI. Vale's extensive experience in global logist...

Company Fundamentals
Bullish
42 minutes ago
JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...

Market News
Bullish
42 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App